29 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp01987 | Buforin 2 | TRSSRAGLQFPVGRVHRLLRK | Asiatic toad | Disruption of electric potential of the cell membrane; Necrosis, Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | IC50 : 90-95 µg/ml |
| dbacp02105 | Buforin2 | TRSSRAGLQFPVGRVHRLLRK | Asiatic toad | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 5% Cytotoxicity at 0.5 µg/ml |
| dbacp02512 | Citropin1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 60% Cytotoxicity at 0.5 µg/ml |
| dbacp02513 | Citropin1.1 | GLFDVIKKVASVIGGL | Australian blue mountains tree frog | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 60% Cytotoxicity at 0.5 µg/ml |
| dbacp02647 | Demegen P-113 | AKRHHGYKRKFH | Amphibian skin peptide | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 15% Cytotoxicity at 0.5 µg/ml |
| dbacp04487 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : >150 µg/ml |
| dbacp04505 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 16 µg/ml |
| dbacp04515 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 17 µg/ml |
| dbacp04531 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 19 µg/ml |
| dbacp04796 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04797 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 60% cell viability at 50 µM |
| dbacp04802 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04803 | N29D | PDEDAINDALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 60% cell viability at 50 µM |
| dbacp04808 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04809 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 40% cell viability at 50 µM |
| dbacp04814 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | 100% cell viability at 5 µM |
| dbacp04815 | N29N | PDEDAINNALNKVCSTGRRQRSICKQLLKK | Synthetic peptide | Apoptotic inducing | Cell viability assay | U-937 | Lymphoma cancer | < 40% cell viability at 50 µM |
| dbacp04866 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | NK-lysin | Cell membrane disintegration | PI-uptake assay | U-937 | Lymphoma cancer | LD50 : 30 µM |
| dbacp05012 | Omiganan MBI-226 | ILRWPWWPWRRK | Cattle neutrophils | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | IC50 : 80 - 85 µg/ml |
| dbacp05013 | Omiganan MBI-226 | ILRWPWWPWRRK | Helical peptide with a predominance of one or more amino acids tryptophane-rich | Disruption of electric potential of the cell membrane; Necrosis; Membranolytic activity leading to apoptosis | MTT/MTS assay | U-937 | Lymphoma cancer | 27% Cytotoxicity at 0.5 µg/ml |
| dbacp05487 | Pexiganan acetate | GIGKFLKKAKKFGKAFVKILKK | Engineered | Disruption of membrane permeability | MTT/MTS assay | U-937 | Lymphoma cancer | 75% Cytotoxicity at 0.5 µg/ml |
| dbacp05489 | Pexiganan MSI-78 | GIGKFLKKAKKFGKAFVKILKK | Helical peptide with a predominance of one or more amino acids tryptophane-rich | Disruption of membrane permeability | MTT/MTS assay | U-937 | Lymphoma cancer | 75% Cytotoxicity at 0.5 µg/ml |
| dbacp05650 | Protegrin 1 | RGGRLCYCRRRFCVCVGR | Alpha helical peptide without cysteines | Not specified | MTT/MTS assay | U-937 | Lymphoma cancer | 61% Cytotoxicity at 0.5 µg/ml |
| dbacp06227 | Temporin A | FLPLIGRVLSGIL | Common frog | Cell membrane disintegration | MTT/MTS assay | U-937 | Lymphoma cancer | 15% cytotoxicity at 0.5 µg/ml |
| dbacp06228 | Temporin A | FLPLIGRVLSGIL | European common frog | Cell membrane disintegration | MTT/MTS assay | U-937 | Lymphoma cancer | 15% cytotoxicity at 0.5 µg/ml |
| dbacp06462 | Varv peptide A (Varv A; Plant defensin) | GLPVCGETCVGGTCNTPGCSCSWPVCTRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture assay | U-937 GTB (lymphoma) | Not found | IC50 : 6 µM |
| dbacp06472 | Varv peptide E (Varv E; Plant defensin) | GLPICGETCVGGTCNTPGCSCSWPVCTRN | Field pansy | Not specified | SRB assay | U-937 GTB (lymphoma) | Not found | IC50 : 4 µM |
| dbacp06557 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 123 µg/ml |
| dbacp06573 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | U-937 | Lymphoma cancer | IC50 : 97 µg/ml |